Nymox Pharmaceutical Corporation (NYMX) News
Filter NYMX News Items
NYMX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NYMX News Highlights
- NYMX's 30 day story count now stands at 2.
- Over the past 2 days, the trend for NYMX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest NYMX News From Around the Web
Below are the latest news stories about NYMOX PHARMACEUTICAL CORP that investors may wish to consider to help them evaluate NYMX as an investment opportunity.
NYMOX UpdateIRVINE, Calif., July 07, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is providing information to address requests it has received for further information concerning recent changes to the Company’s Board of Directors (“Board”) and the Company’s management. Two former employees (the “Former Employees”) of the Company proposed to the Company a potential transaction (the “Proposed Transaction”). The Company, its employees, and the Former Employees |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day off right with a breakdown of the biggest pre-market stock movers traders need to watch on Thursday! |
Why Is Kazia Therapeutics (KZIA) Stock Moving Today?Kazia Therapeutics (KZIA) stock is on the move Thursday after the company received fast-track designation for its paxalisib program. |
Why Is Nymox Pharmaceutical (NYMX) Stock Down 18% Today?Nymox Pharmaceutical (NYMX) stock is falling on Thursday after the company told investors its shares will be delisted tomorrow. |
Nymox Delisting from NASDAQIRVINE, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) today received a Nasdaq Hearing Delist Decision, noting that Nymox has not regained the required $1.00 share price within the 6-month extension period granted by Nasdaq, and hence the Company's shares will be suspended from trading on NASDAQ at the open of business on July 7, 2023. Nymox shares will be moved to the OTC market. The mechanics of trading the stock remain the same, as do |
Nymox Provides Current UpdateIRVINE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to provide a mid-2nd quarter update on ongoing activities. The Company reported last month that it expects to submit an additional new submission for marketing approval of Nymozarfex, the Company's first in class molecular treatment for benign prostate enlargement (BPH). The Company expects to report further details once the application is submitted, which is expected this |
Nymox Provides Corporate UpdateIRVINE, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to provide a current update on the Company's ongoing projects. The Company recently submitted its application for Marketing Authorization Application to the Danish authorities. The application to the Danish authorities was accepted for review in February and is under review at this time. The Company now expects to be making a second new submission in the next 30-60 days. |
Nymox Announces Appointment of Christopher R. Riley as Chief Financial OfficerIRVINE, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce the appointment of Christopher R. Riley as Chief Financial Officer (CFO) of Nymox. Mr. Riley is a globally experienced executive and entrepreneur with many notable successes and has held major positions in large well known corporations. He was CFO for Frito-Lay Australia where he was in charge of the snack food division, and during his tenure he was key execut |
Nymox Officially Granted Extension to Regain Listing RequirementsIRVINE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) has officially been granted by NASDAQ an additional period until July 3, 2023 to regain compliance with NASDAQ listing requirements, the Company reported today. Nymox has recently submitted its Market Approval Application (MAA) for the treatment of benign prostatic hyperplasia, prostate enlargement (BPH), in middle aged and elderly men, one of the most common disorders in the world. |
One Nymox Pharmaceutical Corporation (NASDAQ:NYMX) insider upped their stake by 32% in the previous yearInsiders were net buyers of Nymox Pharmaceutical Corporation's ( NASDAQ:NYMX ) stock during the past year. That is... |